T HE THYROID HORMONE T 3 promotes growth, induces differentiation, and regulates metabolic functions. These biological activities are mediated by the interaction of T 3 with thyroid hormone nuclear receptors (TRs) that are members of the steroid/retinoic acid receptor superfamily. Two TR genes, TR␣ and TR␤, located on human chromosomes 17 and 3, respectively, have been identified. Four T 3 -binding TR isoforms, ␤1, ␤2, ␤3, and ␣1, are generated from these two genes (1, 2). Each TR isoform can be functionally divided into three domains: the amino-terminal A/B domain, the DNA-binding domain C, and the carboxyterminal ligand-binding domain E. Domain C recognizes specific hormone response DNA sequences in the promoter region of T 3 target genes, whereas domain E, besides binding T 3 , participates in transcriptional activation and repression. The gene-regulating activity of TRs is complex. It depends not only on T 3 and the types of thyroid hormone response elements but also on other cellular proteins including coactivators and corepressors (3).
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Resistance to thyroid hormone (RTH) is a syndrome characterized by the resistance of tissues to the action of thyroid hormone. This disease is manifested by elevated levels of circulating thyroid hormone and dysfunction of the negative feedback loop in the pituitary-thyroid axis, resulting in insuppressible TSH. Clinical features include goiter, attentiondeficit hyperactivity disorder, decreased IQ, dyslexia, short stature, decreased weight, tachycardia, cardiac disease, and hypercholesterolemia (4) . RTH can appear sporadically, but most commonly it is a familial syndrome with autosomal dominant inheritance. RTH is caused by mutations in TR␤ (4) . The mutations are clustered in three hot spots in the hormone-binding domain (4, 5) . TR␤ mutants derived from RTH patients have reduced or no T 3 -binding activity and transcriptional capacities. They act in a dominant negative fashion to cause the clinical phenotype (4, 6) .
To study the molecular basis of RTH, we created an RTH mouse model by targeting the PV mutation to the TR␤ gene locus via homologous recombination (TR␤PV mice) (7) . The PV mutation was derived from a patient with severe RTH characterized by attention-deficit hyperactivity disorder, short stature, low weight, goiter, and tachycardia. PV has a unique mutation in exon 10, a C-insertion at the coding nucleotide position 1642 (codon 448) that produces a frame shift in the carboxy-terminal 14 amino acids of TR␤1, resulting in total loss of T 3 binding and transcriptional activities. The pituitary-thyroid axis is mildly impaired in the heterozygous TR␤ PV/ϩ mice. In homozygous TR␤ PV/PV mice, the severe dysfunction of the pituitary-thyroid axis results in an extraordinarily high TSH level despite highly elevated levels of circulating thyroid hormone. TR␤ PV/PV mice also have impaired weight gain and delayed bone development (7) . This phenotype is entirely consistent with that of human RTH, and, therefore, TR␤ PV/PV mice represent a valid model of human RTH.
One of the intriguing observations in RTH patients is a marked variability of resistance in different tissues of the same individual or among kindreds with the same TR␤ gene mutations (4, 6) . How the action of mutant TR␤ is modulated, leading to varying degrees of resistance in tissues, is not clear. The availability of the TR␤PV mouse provides an unusual opportunity to address this question. Using these mice, we recently found that one of the factors that contribute to variability in tissue sensitivity of RTH is the differential distribution of endogenous TR isoforms in tissues (8) . However, differential TR isoform distribution alone is not sufficient to fully account for the abnormal expression patterns of T 3 target genes in different tissues (8) .
Recent studies indicate that the transcriptional activity of wild-type TRs is regulated by coregulatory proteins (3) . In the absence of T 3 , TR represses basal transcriptional activity by binding to corepressors, such as the nuclear corepressor or the silencing mediator of retinoic and thyroid hormone receptor, that are associated with histone deacetylases via an intermediary factor, Sin3 (9, 10) . Binding of T 3 results in dissociation of this corepressor complex from TR, enabling TR to recruit coactivators [e.g. steroid receptor coactivator-1 (SRC-1) and/or other p160 family members] and other cofactors associated with histone acetyltransferase activity, leading to transcriptional activation (3) . Indeed, the activation role of SRC-1 has also been shown in vivo in that mice with wild-type receptors, but deficient in SRC-1, exhibit the phenotype of reduced T 3 (11) and steroid hormone insensitivity (12) . The reduced T 3 sensitivity in tissues because of the lack of SRC-1 is TR-subtype dependent (13) . However, whether the lack of SRC-1 in vivo affects tissue resistance because of TR␤ mutants is currently unknown.
In the present study, we asked whether the lack of SRC-1 alters the extent of responsiveness in the pituitary-thyroid axis and impairs growth and bone development, as manifested in TR␤PV mice (7) . We also evaluated the effect of lack of SRC-1 on the abnormal expression patterns of several T 3 target genes in the pituitary and liver. We found that the lack of SRC-1 modulates the degree of responsiveness to thyroid hormone in a tissue-dependent manner. Moreover, the present findings show an expanded role for SRC-1 in modulating not only the functions of wild-type TRs but also actions of TR␤ mutants in vivo.
Materials and Methods

Mouse strains
All animal experiments were performed according to protocols approved by the Animal Care and Use Committee at NIH. The TR␤ PV/PV mice and SRC-1 Ϫ/Ϫ mice were generated as described previously (7, 12) . The TR␤ PV/ϩ and SRC-1 Ϫ/ϩ mice were crossed, and the resultant offspring were backcrossed to each other five or six times to generate offspring with genotypes of TR␤
PV/PV SRC-1 ϩ/ϩ , and TR␤ PV/PV SRC-1 Ϫ/Ϫ mice. They were genotyped by PCR using primers specific for TR␤ and SRC-1 sequences as described (7, 12) . The littermates were used in the comparison of the phenotypes among mice with different genotypes. Mice were fed normal chow and tap water and housed under 12-h light/12-h dark cycles at 22 C. For Northern analysis of CYP7A mRNA in liver, mice were fed fat-free test diet (ICN Biomedicals, Costa Mesa, CA) for 5 d before being killed.
Hormone assays
Sera were collected from adult mice (2-5 months old). Serum levels of total T 4 and T 3 were determined by using a GammaCoat T4 or T3 assay RIA kit (DiaSolin, Stillwater, MN) according to the manufacturer's instructions. TSH levels in serum were measured as previously described (7, 14) but using the RIA kit purchased from National Hormone and Peptide Program, Harbor-UCLA Medical Center (Torrance, CA). Sera from overnight-fasted mice were used for determination of total cholesterol levels in accordance with the directions provided by the test kit manufacturer (cholesterol, total, and cholesterol calibrator kits; Sigma, St. Louis, MO).
Northern blot analysis
Total RNA from three mice (3 months old) was prepared as described for Northern blot analysis (7) . After electrophoresis, RNA was transferred onto membranes (Hybond-Nϩ; Amersham Pharmacia, Boston, MA), which were hybridized with appropriate probes. The cDNA clones for TSH␤, GH, and cholesterol 7␣-hydroxylase (CYP7A) were labeled with [␣-32 P]dCTP by using a Prime It II (Stratagene Cloning Systems, La Jolla, CA). For quantification, the intensities of the mRNA bands were normalized against the intensities of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (n ϭ 3). The blots were stripped and rehybridized with a 32 P-labeled GAPDH cDNA. Quantification was performed with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) or NIH Image 1.61.
Histological examination
Thyroid glands were fixed in 10% neutral buffered formalin and subsequently embedded in paraffin. Five-micrometer-thick sections were prepared and stained with hematoxylin and eosin for microscopic examination.
The areas of individual follicles were determined by using Photoshop software (version 7.0, Adobe, San Jose, CA) with the histogram function that allows the measurement of areas in pixels at a fixed magnification and digital resolution. Random selection of follicles (n ϭ 100) was facilitated by the use of the magic wand tool in Photoshop, set at a tolerance that selected the entire follicle, including epithelial cells.
The morphological determination of the normal, hyperplastic, and papillary hyperplastic follicular cells was performed, first by identification of the normal follicular cells. The remaining cells constituted a group termed hyperplastic cells. Further subgrouping identified the hyperplastic cells that had at least one single frond. This subgroup was termed papillary hyperplastic cells. A microscope equipped with highresolution objectives was used to identify the hyperplastic follicular cells with or without fronds and fibrovascular stalks (papillary hyperplastic cells). Multiple samples with multiple observations were used to make the determinations. For consistency, blinded samples were examined by a single pathologist using the same criteria.
Data analysis
All data are expressed as mean Ϯ se. P values were calculated using one-way ANOVA. Follow-up tests were performed using the Fisher's protected least square difference. P Ͻ 0.05 was considered significant.
Results
Lack of SRC-1 intensifies the dysfunction of the pituitarythyroid axis in TR␤PV mice
Thyroid hormone production is tightly regulated by a feedback mechanism in that pituitary TSH is suppressed by elevated levels of thyroid hormone. To understand the role of SRC-1 in the regulation of the pituitary-thyroid axis, we first compared the circulating levels of thyroid hormone in wild-type and TR␤PV mice with or without SRC-1 ( Fig. 1) . Lack of SRC-1 resulted in mean total T 4 (TT4) that was 1.7-fold higher (TR␤ ϩ/ϩ SRC-1 ϩ/ϩ ϭ 4.9 Ϯ 0.3 g/dl, n ϭ 10;
. Consistent with findings in RTH patients who have a mutated TR␤ gene (7, 11) , mean TT4 was 2.2-fold higher in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice (11.0 Ϯ 0.8 g/dl, n ϭ 13) than TR␤ ϩ/ϩ mice. Importantly, lack of SRC-1 in TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice led to an additional 2.1-fold increase in TT4 (23.40 Ϯ 0.8 g/dl, n ϭ 20). There were, however, no significant differences in the highly elevated mean TT4 levels between the TR␤ PV/PV SRC-1 ϩ/ϩ and TR␤ PV/PV SRC-1 Ϫ/Ϫ mice (83.7 Ϯ 7.2 g/dl, n ϭ 10 and 96.5 Ϯ 5.4 g/dl, n ϭ 20, respectively; P ϭ 0.115).
Lack of SRC-1 in wild-type and TR␤PV mice resulted in a similar effect on the total T 3 (TT3) levels (Fig. 1B) . Mice deficient in SRC-1 (TR␤ ϩ/ϩ SRC-1 Ϫ/Ϫ mice) had a mean TT3 concentration (2.1 Ϯ 0.1 ng/ml, n ϭ 15) that was 1.5-fold that of wild-type mice (1.33 Ϯ 0.05 ng/ml, n ϭ 10). Consistent with observations in RTH patients who have a mutated TR␤ gene (7, 11) , the mean TT3 concentration was elevated 1.7-fold in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice (2.3 Ϯ 0.1 ng/ml, n ϭ 12), compared with TR␤ ϩ/ϩ mice. The lack of SRC-1 in TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice further increased the mean TT3 concentration 2.0-fold (4.5 Ϯ 0.3 ng/ml, n ϭ 15). The highly elevated mean TT3 concentration in TR␤ PV/PV SRC-1 ϩ/ϩ mice (20.0 Ϯ 3.4 ng/ml, n ϭ 10) was not significantly different from that in TR␤ PV/PV SRC-1 Ϫ/Ϫ mice (28.3 Ϯ 4.2 ng/ml, n ϭ 15; P ϭ 0.106). These results indicate that lack of SRC-1 increased the circulating levels of thyroid hormones in TR␤ PV/ϩ mice but not significantly in TR␤ PV/PV mice. The lack of effect of the absence of SRC-1 on TT4 and TT3 could be because the response has reached its maximum in the presence of two mutated TR␤ genes.
The extent of thyroid gland enlargement correlated with the magnitude of the elevation of serum thyroid hormone concentration in TR␤PV mice. As shown in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice. The lack of SRC-1 did not significantly affect the degree of enlargement of thyroid glands in TR␤ PV/PV SRC-1 ϩ/ϩ vs. TR␤ PV/PV SRC-1 Ϫ/Ϫ mice (41.6 Ϯ 5.2 mg, n ϭ 10, vs. 57.8 Ϯ 10.5 mg, n ϭ 10, P ϭ 0.08).
Consistent with the weight increase in the thyroids, histological evaluation indicated that lack of SRC-1 significantly increased the size of the individual follicles. The average area of the follicles of TR␤ ϩ/ϩ SRC-1 Ϫ/Ϫ mice (Fig. 3B ) was 2358 Ϯ 178 pixels/follicle (n ϭ 100; mean Ϯ sd), which was 1.7-fold that of TR␤ ϩ/ϩ SRC-1 ϩ/ϩ mice (1420 Ϯ 27 pixels/follicle; Fig.  3A) . The average area of follicles of TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice (Fig. 3D ) was 4817 Ϯ 716 pixels/follicle, which was 1.6-fold that of TR␤ PV/ϩ SRC-1 ϩ/ϩ mice (3015 Ϯ 319 pixels/follicle; Fig. 3C ). More dramatic changes were detected in the thyroids of TR␤ PV/PV mice. The epithelium of the thyroids in TR␤ PV/PV SRC-1 ϩ/ϩ mice exhibited extensive hyperplasia (Fig. 3E) . Lack of SRC-1 in TR␤ PV/PV SRC-1 Ϫ/Ϫ mice intensified the pathological progression of the thyroid gland to produce florid adenomatous hyperplasia with a papillary pattern and papillary containing fibrovascular cores, reminiscent of papillary neoplasia (Fig. 3F) .
Because the follicles of the thyroid glands in TR␤ PV/PV SRC-1 ϩ/ϩ (Fig. 3E) and TR␤ PV/PV SRC-1 Ϫ/Ϫ (Fig. 3F ) mice were heterogeneous, we developed a way to quantify the degree of pathological progression. We characterized each thyroid according to the percentage of the follicles that was normal, hyperplastic but without papillary structure, or hyperplastic with papillary pattern. As shown in Fig. 3G , the majority (ϳ75%) of the follicles in TR␤ PV/PV SRC-1 ϩ/ϩ mice were hyperplastic (bar 3, Fig. 3G ), whereas the majority (ϳ60%) in TR␤ PV/PV SRC-1 Ϫ/Ϫ mice were hyperplastic with papillary patterns (bar 6, Fig. 3G ), an indication that the lack of SRC-1 intensified the pathological progression in the epithelium of the thyroids in TR␤ PV/PV SRC-1 Ϫ/Ϫ mice. To understand the effect of SRC-1 on the function of the pituitary, we determined the serum TSH levels. Figure 4 shows that despite elevated thyroid hormone, there was no significant difference between the serum TSH level in TR␤ ϩ/ϩ mice (n ϭ 18; P ϭ 0.198). The lack of effect of SRC-1 on TSH could be because the response has reached its maximum in the presence of two mutated TR␤ genes. However, the extent of the increased weight of thyroid glands correlated with the elevated TSH levels. 
Lack of SRC-1-impaired growth in TR␤PV mice
Consistent with previous results (7) (Fig. 5B  vs. 5A) . Interestingly, lack of SRC-1 led to impaired weight gain in TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice (Fig. 5B) . A significantly lower weight gain (9 -12% lower) was observed up to 10 wk of age for TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice, compared with their TR␤ PV/ϩ SRC-1 ϩ/ϩ littermates (P Ͻ 0.05). Importantly, the lack of SRC-1 did not significantly affect the weight gain in mice without the mutation in the TR␤ gene (Fig. 5A) . In fact, after wk 8, TR␤ ϩ/ϩ SRC-1 Ϫ/Ϫ mice tended to gain significantly more weight (ϳ6% increase at 12 wk of age) than did TR␤ (Fig. 5C ). Similar results were found for male mice (data not shown).
In a separate study in which the pups were weighed beginning at the age of 1 wk, no significant differences in weight gains between TR␤ PV/ϩ SRC-1 ϩ/ϩ and TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice were detected until the age of 4 wk. The significant differences in weight gain between TR␤ ϩ/ϩ SRC-1 ϩ/ϩ and TR␤ PV/PV SRC-1 ϩ/ϩ were found at the age of 3 wk and thereafter. No significant differences in body lengths were found (our unpublished data).
Lack of SRC-1 does not alter the resistance of the liver in the regulation of serum cholesterol
To understand whether the lack of SRC-1 alters the responsiveness of the liver to thyroid hormone, we measured the serum cholesterol that is an in vivo marker of thyroid hormone action. Thyroid hormone is known to lower cholesterol levels. The blunted response in serum cholesterol after administration of thyroid hormone is commonly used as a diagnostic test for assessing RTH in peripheral tissues (6) . Figure 6 shows that, compared with the wild-type mice (bar 1; n ϭ 14), TR␤ PV/ϩ SRC-1 ϩ/ϩ mice exhibited the phenotype of resistance in the liver by failing to properly respond to the elevated level of thyroid hormone, as indicated by no repression of the cholesterol levels (bar 3; n ϭ 19). Lack of SRC-1 did not significantly change the total cholesterol levels in mice without PV mutation (bar 2; n ϭ 19; P ϭ 0.694) or in mice with one PV allele (bar 4; n ϭ 19; P ϭ 0.151). More dramatic resistance of the liver to the action of thyroid hormone was detected in TR␤ PV/PV SRC-1 ϩ/ϩ mice in that their serum cholesterol levels were significantly higher than those of TR␤ ϩ/ϩ SRC-1 ϩ/ϩ mice (Fig. 6 , bar 5 vs. bar 1; 1.35-fold; n ϭ 19). Lack of SRC-1, however, did not further increase the cholesterol levels in TR␤ PV/PV SRC-1 Ϫ/Ϫ mice (an increase of 1.44-fold; bar 6 vs. bar 1, n ϭ 19; P ϭ 0.343).
Lack of SRC-1 lessens impairment of bone development in TR␤
PV/PV mice Figure 7 shows that lack of SRC-1 did not significantly affect the development of the tibia in mice without the mutation of the TR␤ gene (18.42 Ϯ 0.19 mm, n ϭ 11 and 17.93 Ϯ 0.33 mm, n ϭ 6 for TR␤ ϩ/ϩ SRC-1 ϩ/ϩ mice and TR␤ ϩ/ϩ SRC-1 Ϫ/Ϫ mice, respectively; P ϭ 0.19) or in mice with one PV allele (17.94 Ϯ 0.14 mm, n ϭ 10 and 18.21 Ϯ 0.15 mm, n ϭ 10 for TR␤ PV/ϩ SRC-1 ϩ/ϩ mice and TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice, respectively; P ϭ 0.537). Unexpectedly, we found that the lack of SRC-1 significantly lessened impairment of tibial growth in TR␤ PV/PV mice (16.96 Ϯ 0.14 mm, n ϭ 9 and 17.58 Ϯ 0.08 mm, n ϭ 7 for TR␤ PV/PV SRC-1 ϩ/ϩ mice and TR␤ PV/PV SRC-1 Ϫ/Ϫ mice, respectively; P Ͻ 0.05).
Lack of SRC-1 intensifies the abnormal expression patterns of TSH␤ and GH genes in the pituitary
To gain insight into how SRC-1 modulates the target-tissue responsiveness in TR␤PV mice, we examined the effect of the lack of SRC-1 on the expression patterns of T3-target genes in tissues. We first examined the expression of the TSH␤ gene in TR␤PV mice. As shown in Fig. 8 , the lack of SRC-1 did not significantly change the expression of the TSH␤ gene in TR␤ ϩ/ϩ mice ( Fig. 8A-a, lanes 1-3 vs. 4 -5, and Fig. 8B , bar 2 vs. bar 1, for TR␤ ϩ/ϩ SRC-1 ϩ/ϩ and TR␤ ϩ/ϩ SRC-1 Ϫ/Ϫ , respectively; P ϭ 0.241). Consistent with our previous report (7), the expression of the TSH␤ gene was not repressed despite elevated thyroid hormones in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice. The lack of SRC-1 accentuated the resistance to thyroid hormone in the pituitary by a 1.4-fold increase in the expression of the TSH␤ mRNA (Fig. 8B, bar 4 vs. 3; P Ͻ 0.05). Although the expression of the TSH␤ mRNA was greatly augmented in TR␤ PV/PV SRC-1 ϩ/ϩ (Fig. 8B, bar 5 vs. bar 1) and TR␤ PV/PV SRC-1 Ϫ/Ϫ mice (Fig. 8B, bar 6 vs. bar 2) , the lack of SRC-1 did not significantly affect the expression of the TSH␤ gene in TR␤ PV/PV mice (Fig. 8B, bar 6 vs. bar 5; P ϭ 0.362). These results indicate that the effect of the lack of SRC-1 on the expression of the TSH␤ mRNA is consistent with that of the serum levels of TSH (see Fig. 4 ).
The expression of the GH gene is positively regulated by T 3 . Figures 8A-b and 8C show that instead of being activated by elevated thyroid hormone in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice, the expression of the GH mRNA had no increase, compared with that in TR␤ ϩ/ϩ SRC-1 ϩ/ϩ mice (Fig. 8C, bar 3 vs. bar 1) . No changes in the expression of the GH mRNA because of the lack of SRC-1 were detected between TR␤ PV/ϩ SRC-1 ϩ/ϩ and TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice (Fig. 8C, bar 4 vs. bar 3) , indicating that the lack of SRC-1 did not further enhance the dominant negative effect of PV on the expression of the GH mRNA. A strong repression of GH mRNA (80% reduction) was observed in TR␤ PV/PV SRC-1 ϩ/ϩ mice (Fig. 8C, bar 5 vs. bar 1 ). An additional small reduction (ϳ10%) was observed in TR␤ PV/PV mice deficient in SRC-1 (Fig. 8C, bar 6 vs. bar 5). As shown in Fig. 8A -c, the expression of GAPDH was used to
Comparison of the expression of the TSH␤ and GH genes in the pituitary of TR␤PV mice with or without SRC-1. Northern blot analysis of TSH␤ mRNA (A-a) and GH mRNA (A-b) were determined using 3 g/lane of total RNA from three adult male mice. The loading of RNA was normalized by stripping the blots and rehybridizing with [ 32 P]-labeled GAPDH (A-c). After quantification, the relative mRNA expression is shown for TSH␤ (B) and for GH (C). Data are expressed as mean Ϯ SE. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; NS, not significant. normalize the expression of the TSH␤ mRNA in Fig. 8A -a and the GH mRNA in Fig. 8A-b .
Lack of SRC-1 does not alter the PV-mediated abnormal expression pattern of the CYP7A gene in TR␤PV mice
T 3 is important not only for the uptake of cholesterol by the liver but also for the hepatic degradation of cholesterol into bile acids. The rate-limiting enzyme in the latter process, CYP7A, is activated by T 3 at the transcriptional level and is therefore a direct T 3 positively regulated gene (15, 16) . We, therefore, evaluated the effect of SRC-1 on the expression of CYP7A mRNA in TR␤PV mice. Figure 9 shows that no activation was detected in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice (Fig. 9B, bar  3 vs. bar 1) in the face of elevated serum thyroid hormone. The lack of SRC-1 did not change the expression of the CYP7A gene in the liver of either TR␤ ϩ/ϩ SRC-1 Ϫ/Ϫ mice (Fig. 9B, bar  2 vs. bar 1) or TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice (Fig. 9B, bar 4 vs. bar 3) . In TR␤ PV/PV SRC-1 ϩ/ϩ mice, instead of being activated by the highly elevated thyroid hormone (see Fig. 1, A and B) , the expression of CYP7A mRNA was repressed 80% (TR␤ PV/PV SRC-1 Ϫ/Ϫ mice; Fig. 9B , bar 5 vs. bar 1). This extent of repression was not altered in mice deficient in SRC-1 (Fig. 9B, bar 6 vs. bar 5; P ϭ 0.979). These results indicate that, consistent with findings from serum cholesterol levels (Fig. 6) , the expression the CYP7A gene mediated by PV is not affected by the lack of SRC-1.
Discussion
The present study showed that the lack of SRC-1 led to an array of changes in the phenotypic expression of TR␤PV mice. These changes can be roughly classified into three groups. The first group of changes relates to patterns found in the pituitary-thyroid axis and in growth/weight gain. Namely, lack of SRC-1 enhanced resistance in TR␤ PV/ϩ mice but had no significant effect on TR␤ PV/PV mice. Thus, serum TT4, TT3, and TSH levels and the weight of thyroid glands in TR␤ PV/ϩ mice were markedly increased in mice deficient in SRC-1. In TR␤ PV/ϩ SRC-1 ϩ/ϩ mice in which no manifestation of abnormality in weight gain was detected, compared with TR␤ ϩ/ϩ SRC-1 ϩ/ϩ mice, the lack of SRC-1 led to the manifestation of impairment in growth. However, no enhancement in these two phenotypes was found in TR␤ PV/PV mice by the lack of SRC-1. The second group of changes is exemplified in the liver in that no alterations in serum total cholesterol levels were detected by the lack of SRC-1 in either TR␤ PV/ϩ or TR␤ PV/PV mice. The third group is illustrated by the impairment of bone development in that the lack of SRC-1 had no significant effect on the extent of the impaired bone development in TR␤ PV/ϩ mice but lessened the extent of impairment in TR␤ PV/PV mice. These results suggest that the effect of the lack of SRC-1 on resistance is target tissue dependent. However, we cannot exclude the possibility that the complex phenotype exhibited by TR␤ PV/PV SRC-1 Ϫ/Ϫ mice could be from the contributions of other coregulatory proteins because of secondary effects from the lack of SRC-1 (e.g. possible compensatory effect). Recently, on the basis of studies using mice deficient in TR␣ and SRC-1 (TR␣ 0/0 SRC-1 Ϫ/Ϫ ) as well as in TR␤ and SRC-1 (TR␤ Ϫ/Ϫ SRC-1 Ϫ/Ϫ ), Sadow et al. (13, 17) reported that SRC-1 also modulates the in vivo actions of wild-type TRs in several T 3 target tissues. The lack of SRC-1 increases the extent of resistance in the pituitary-thyroid axis of TR Ϫ/Ϫ mice in that an additional 1.6-, 2.9-, and 2.8-fold elevation in TT4, TT3, and TSH serum concentrations, respectively, were detected (15) . A similar but slightly lower additional increase in TT4, TT3, and TSH concentrations caused by the lack of SRC-1 (1.7-, 1.7-, and 2.2-fold, respectively) in TR␣ 0/0 SRC-1 Ϫ/Ϫ mice was also observed. No impairment in weight gain is apparent in mice deficient in either TR␤ or SRC-1, but the lack of SRC-1 led to the manifestation of impaired weight gain in TR␤ Ϫ/Ϫ SRC-1 Ϫ/Ϫ mice (13) . However, the lack of SRC-1 does not further increase the extent of impaired weight gain already exhibited in TR␣ 0/0 mice (13). In the heart, the lack of SRC-1 significantly lowers the basal heart rates in mice with the presence of both TR isoforms (SRC-1 Ϫ/Ϫ mice), but no further significant changes were discernible in TR␤ Ϫ/Ϫ SRC-1 Ϫ/Ϫ mice. A relatively small (1.4-fold), but significant, additional lowering of the heart rates in TR␣ 0/0 mice was observed along with the lack of SRC-1 (13) . These studies demonstrate that, similar to what was found in TR␤PV mice, SRC-1 affects the in vivo activity of TRs in a tissue-dependent manner. The present findings highlight an expanded role of SRC-1 in that it not only modulates the in vivo functions of wild-type TRs (11) (12) (13) 17) but also plays a critical role in the action of mutant TR␤ in vivo.
To understand how the lack of SRC-1 alters the target tissue responsiveness, we ascertained the effect of the lack of SRC-1 on the expression of several T 3 -target genes. Previously it was shown that the expression of the TSH␤ gene in the pituitary was not repressed in TR␤ PV/ϩ mice, notwithstanding increased thyroid hormone (7) . The present study shows that the lack of SRC-1 further increased the expression of TSH␤ mRNA (1.4-fold) in TR␤ PV/ϩ mice. That SRC-1 plays a functional role in the increased expression of the TSH␤ gene is supported by the studies in TR␤ Ϫ/Ϫ SRC-1 Ϫ/Ϫ mice (17) . In mice deficient in either TR␤ or SRC-1, a 3.3-or 1.3-fold increase in the expression of the TSH␤ mRNA was detected. The lack of SRC-1 (TR␤ Ϫ/Ϫ SRC-1 Ϫ/Ϫ mice) led to an 8.9-fold increase in the expression of the TSH␤ mRNA (17) .
In mice with two mutated TR␤ genes, however, the lack of SRC-1 did not significantly increase further the already elevated TSH␤ mRNA (Fig. 8A) . One possibility we propose is that the difference in the effect of the lack of SRC-1 on the expression of TSH␤ mRNA is due to the number of the mutated TR␤ alleles. In TR␤ PV/ϩ mice, the lack of SRC-1 could compromise the transcriptional activity of the remaining wild-type TR␤ allele in the pituitary of TR␤ PV/ϩ mice, thereby further increasing the abnormal expression of the TSH␤ gene. This notion is supported by the DNA-binding experiments reported earlier in that, in addition to the detection of TR␤/PV heterodimers, TR␤/RXR heterodimers were also detected in TR␤ PV/ϩ mice (8) . In the presence of T 3 and SRC-1, TR␤/RXR heterodimers presumably mediate the normal function of repressing the expression of the TSH␤ gene. Therefore, in TR␤ PV/ϩ SRC-1 ϩ/ϩ mice, only one mutated TR␤ allele acts to interfere the transcriptional activity of the wild-type TRs (one copy of the TR␤ gene and two copies of the TR␣ genes), leading to mild abnormal expression of the TSH␤ gene.
However, the lack of SRC-1 weakens the normal functions of wild-type TR␤ and TR␣1, thereby resulting in increased abnormal regulation of the TSH␤ gene in TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice. In TR␤ PV/PV SRC-1 Ϫ/Ϫ mice, both the TR␤ genes are mutated. TR␤ is known to be the predominant TR isoform in the pituitary (18) . Because the expression of PV is driven by the same promoter as the TR␤ gene, the more abundantly expressed PV (compared with TR␣1) exerted a strong dominant negative effect on the abnormal up-regulation of the TSH␤ gene that was not significantly affected by the lack of SRC-1 in the pituitary of TR␤ PV/PV mice. This finding suggests that the weakening effect of SRC-1 on the wild-type TR␣1 plays a minor role in the regulation of the TSH␤ gene. This notion is supported by the findings in the expression of the TSH␤ mRNA in TR␤ Ϫ/Ϫ and TR␣ 0/0 mice. The lack of TR␤ has a more severe effect on the dysregulation of the TSH␤ gene than does the lack of TR␣1 (19 -21) . These results indicate the critical role of the interplay of a differential expression of TR isoforms and SRC-1 in the manifestation of resistance in target tissues.
With a limited number of T 3 target genes that could be evaluated, there was a good correlation in the effect of the lack of SRC-1 between the mRNA expression levels of TSH␤ and the serum levels of TSH. In the liver, there was also a good correlation between the expression of the CYP7A gene and the serum cholesterol levels in that the lack of SRC-1 had no effect on either the PV-mediated abnormal expression patterns of the CYP7A gene or the elevated cholesterol levels. However, no correlation in the effect of the lack of SRC-1 on the expression of the GH gene with the growth/weight gain was observed. Namely, in the TR␤ PV/ϩ SRC-1 Ϫ/Ϫ mice, the lack of SRC-1 did not change the expression of the GH gene, whereas the lack of SRC-1 did lead to the manifestation of growth retardation. In TR␤ PV/PV mice, the PV-mediated repression of the GH gene was further intensified, but no further impairment in growth/weight gain was observed in the absence of SRC-1. These results suggest that PV-mediated growth impairment requires the participation of other genes that are yet to be uncovered.
The present studies demonstrate that the target-tissue resistance is subject to multifactor combinatorial regulation. The interplay of tissue-dependent TR isoform distribution, coactivators such as SRC-1, and the environment of local promoters of T 3 -target genes leads to variable tissue resistance to thyroid hormone, as demonstrated in TR␤PV mice deficient in SRC-1. Recently a large number of coregulatory proteins have been isolated (3, 22) . Some are general and some are tissue and/or receptor specific. This would mean that there are numerous combinatorial possibilities in the modulation of tissue responsiveness to thyroid hormone. Thus, it should not be a surprise that kindred with the same TR␤ mutation manifest different degrees of resistance in the same tissues or exhibit different spectra of resistance in different tissues within the same patient. With the lessons learned from the TR␤PV mouse model, it should be possible to design better strategies to treat RTH patients.
